Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Idiopathic Pulmonary Fibrosis-Pipeline Review, H1 2015

Idiopathic Pulmonary Fibrosis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Idiopathic Pulmonary Fibrosis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Idiopathic Pulmonary Fibrosis-Pipeline Review, H1 2015', provides an overview of the Idiopathic Pulmonary Fibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Idiopathic Pulmonary Fibrosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Idiopathic Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Idiopathic Pulmonary Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Idiopathic Pulmonary Fibrosis Overview 9

Therapeutics Development 10

Pipeline Products for Idiopathic Pulmonary Fibrosis-Overview 10

Pipeline Products for Idiopathic Pulmonary Fibrosis-Comparative Analysis 11

Idiopathic Pulmonary Fibrosis-Therapeutics under Development by Companies 12

Idiopathic Pulmonary Fibrosis-Therapeutics under Investigation by Universities/Institutes 17

Idiopathic Pulmonary Fibrosis-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Idiopathic Pulmonary Fibrosis-Products under Development by Companies 21

Idiopathic Pulmonary Fibrosis-Products under Investigation by Universities/Institutes 25

Idiopathic Pulmonary Fibrosis-Companies Involved in Therapeutics Development 26

AdAlta Pty Ltd. 26

Aeolus Pharmaceuticals, Inc. 27

AnaptysBio, Inc. 28

Auspex Pharmaceuticals, Inc. 29

Biogen Idec Inc. 30

Bioneer Corporation 31

BiOrion Technologies B.V. 32

Boehringer Ingelheim GmbH 33

Bristol-Myers Squibb Company 34

Carolus Therapeutics, Inc. 35

Celgene Corporation 36

Chong Kun Dang Pharmaceutical Corp. 37

Compugen Ltd. 38

F. Hoffmann-La Roche Ltd. 39

FibroGen, Inc. 40

Five Prime Therapeutics, Inc. 41

GenKyoTex S.A. 42

Gilead Sciences, Inc. 43

GlaxoSmithKline plc 44

HanAll Biopharma Co., Ltd. 45

Histocell S.L. 46

iBio, Inc. 47

ImmuneWorks, LLC 48

Inventiva SAS 49

Kadmon Corporation, LLC 50

Kasiak Research Pvt. Ltd. 51

Kyorin Pharmaceutical Co., Ltd. 52

Lanthio Pharma B.V. 53

LTT Bio-Pharma Co., Ltd. 54

MedImmune, LLC 55

Moerae Matrix, Inc. 56

MSM Protein Technologies, Inc. 57

Pacific Therapeutics Ltd. 58

Pharmaxis Limited 59

Progenra, Inc. 60

Promedior, Inc. 61

ProMetic Life Sciences Inc. 62

Pulmatrix, Inc. 63

Sanofi 64

Therametrics holding AG 65

Idiopathic Pulmonary Fibrosis-Therapeutics Assessment 66

Assessment by Monotherapy Products 66

Assessment by Combination Products 67

Assessment by Target 68

Assessment by Mechanism of Action 71

Assessment by Route of Administration 73

Assessment by Molecule Type 75

Drug Profiles 77

(pentoxifylline + acetylcysteine)-Drug Profile 77

AEOL-10150-Drug Profile 78

AM-0010-Drug Profile 81

Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis-Drug Profile 82

Antisense RNAi Oligonucleotide for COPD and IPF-Drug Profile 83

BMS-986020-Drug Profile 84

BOT-191-Drug Profile 85

CC-539-Drug Profile 86

CC-90001-Drug Profile 87

CGEN-25009-Drug Profile 88

CKD-942-Drug Profile 89

CT-2009-Drug Profile 90

FG-3019-Drug Profile 91

FPA-008-Drug Profile 93

GKT-137831-Drug Profile 94

GKT-901-Drug Profile 95

HC-016-Drug Profile 96

HL-156FIB-Drug Profile 97

HR-017-Drug Profile 98

IBIOCFB-03-Drug Profile 99

ICG-001-Drug Profile 100

interferon gamma-1b-Drug Profile 101

IVA-337-Drug Profile 102

IW-001-Drug Profile 103

KBP-7018-Drug Profile 104

KD-025-Drug Profile 105

lebrikizumab-Drug Profile 107

LP2-Drug Profile 109

LT-0011-Drug Profile 110

LTI-03-Drug Profile 111

MMI-0100-Drug Profile 112

Monoclonal Antibody for Idiopathic Pulmonary Fibrosis-Drug Profile 113

MSM-735-Drug Profile 114

NAS-911-Drug Profile 115

nintedanib-Drug Profile 117

omipalisib-Drug Profile 121

PBF-1250-Drug Profile 122

PBI-4050-Drug Profile 123

pirfenidone-Drug Profile 124

PRM-151-Drug Profile 125

PUR-1500-Drug Profile 127

PXS-25-Drug Profile 128

PXS-4820-Drug Profile 129

PXS-64-Drug Profile 130

Refacell-IPF-Drug Profile 131

RNAi Oligonucleotides for Idiopathic Pulmonary Fibrosis-Drug Profile 132

SAR-156597-Drug Profile 133

SD-560-Drug Profile 134

simtuzumab-Drug Profile 135

Small Molecule 2 for Chronic Respiratory Diseases-Drug Profile 137

Small Molecules to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis-Drug Profile 138

Small Molecules to Inhibit LOXL2 for Oncology and Fibrosis-Drug Profile 139

Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis-Drug Profile 140

SPL-334-Drug Profile 141

Stem Cell Therapy for Idiopathic Lung Fibrosis-Drug Profile 142

Stem Cell Therapy for Lung Fibrosis-Drug Profile 143

STX-100-Drug Profile 144

TD-139-Drug Profile 145

tipelukast-Drug Profile 146

tralokinumab-Drug Profile 148

vismodegib-Drug Profile 150

ZL-2102-Drug Profile 153

Idiopathic Pulmonary Fibrosis-Recent Pipeline Updates 154

Idiopathic Pulmonary Fibrosis-Dormant Projects 193

Idiopathic Pulmonary Fibrosis-Discontinued Products 194

Idiopathic Pulmonary Fibrosis-Product Development Milestones 195

Featured News & Press Releases 195

Appendix 203

Methodology 203

Coverage 203

Secondary Research 203

Primary Research 203

Expert Panel Validation 203

Contact Us 203

Disclaimer 204

List of Tables

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2015 14

Number of Products under Development for Idiopathic Pulmonary Fibrosis-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 17

Number of Products under Development by Companies, H1 2015 (Contd..1) 18

Number of Products under Development by Companies, H1 2015 (Contd..2) 19

Number of Products under Development by Companies, H1 2015 (Contd..3) 20

Number of Products under Investigation by Universities/Institutes, H1 2015 21

Comparative Analysis by Late Stage Development, H1 2015 22

Comparative Analysis by Clinical Stage Development, H1 2015 23

Comparative Analysis by Early Stage Development, H1 2015 24

Products under Development by Companies, H1 2015 25

Products under Development by Companies, H1 2015 (Contd..1) 26

Products under Development by Companies, H1 2015 (Contd..2) 27

Products under Development by Companies, H1 2015 (Contd..3) 28

Products under Investigation by Universities/Institutes, H1 2015 29

Idiopathic Pulmonary Fibrosis-Pipeline by AdAlta Pty Ltd., H1 2015 30

Idiopathic Pulmonary Fibrosis-Pipeline by Aeolus Pharmaceuticals, Inc., H1 2015 31

Idiopathic Pulmonary Fibrosis-Pipeline by AnaptysBio, Inc., H1 2015 32

Idiopathic Pulmonary Fibrosis-Pipeline by Auspex Pharmaceuticals, Inc., H1 2015 33

Idiopathic Pulmonary Fibrosis-Pipeline by Biogen Idec Inc., H1 2015 34

Idiopathic Pulmonary Fibrosis-Pipeline by Bioneer Corporation, H1 2015 35

Idiopathic Pulmonary Fibrosis-Pipeline by BiOrion Technologies B.V., H1 2015 36

Idiopathic Pulmonary Fibrosis-Pipeline by Boehringer Ingelheim GmbH, H1 2015 37

Idiopathic Pulmonary Fibrosis-Pipeline by Bristol-Myers Squibb Company, H1 2015 38

Idiopathic Pulmonary Fibrosis-Pipeline by Carolus Therapeutics, Inc., H1 2015 39

Idiopathic Pulmonary Fibrosis-Pipeline by Celgene Corporation, H1 2015 40

Idiopathic Pulmonary Fibrosis-Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 41

Idiopathic Pulmonary Fibrosis-Pipeline by Compugen Ltd., H1 2015 42

Idiopathic Pulmonary Fibrosis-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 43

Idiopathic Pulmonary Fibrosis-Pipeline by FibroGen, Inc., H1 2015 44

Idiopathic Pulmonary Fibrosis-Pipeline by Five Prime Therapeutics, Inc., H1 2015 45

Idiopathic Pulmonary Fibrosis-Pipeline by GenKyoTex S.A., H1 2015 46

Idiopathic Pulmonary Fibrosis-Pipeline by Gilead Sciences, Inc., H1 2015 47

Idiopathic Pulmonary Fibrosis-Pipeline by GlaxoSmithKline plc, H1 2015 48

Idiopathic Pulmonary Fibrosis-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 49

Idiopathic Pulmonary Fibrosis-Pipeline by Histocell S.L., H1 2015 50

Idiopathic Pulmonary Fibrosis-Pipeline by iBio, Inc., H1 2015 51

Idiopathic Pulmonary Fibrosis-Pipeline by ImmuneWorks, LLC, H1 2015 52

Idiopathic Pulmonary Fibrosis-Pipeline by Inventiva SAS, H1 2015 53

Idiopathic Pulmonary Fibrosis-Pipeline by Kadmon Corporation, LLC, H1 2015 54

Idiopathic Pulmonary Fibrosis-Pipeline by Kasiak Research Pvt. Ltd., H1 2015 55

Idiopathic Pulmonary Fibrosis-Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 56

Idiopathic Pulmonary Fibrosis-Pipeline by Lanthio Pharma B.V., H1 2015 57

Idiopathic Pulmonary Fibrosis-Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015 58

Idiopathic Pulmonary Fibrosis-Pipeline by MedImmune, LLC, H1 2015 59

Idiopathic Pulmonary Fibrosis-Pipeline by Moerae Matrix, Inc., H1 2015 60

Idiopathic Pulmonary Fibrosis-Pipeline by MSM Protein Technologies, Inc., H1 2015 61

Idiopathic Pulmonary Fibrosis-Pipeline by Pacific Therapeutics Ltd., H1 2015 62

Idiopathic Pulmonary Fibrosis-Pipeline by Pharmaxis Limited, H1 2015 63

Idiopathic Pulmonary Fibrosis-Pipeline by Progenra, Inc., H1 2015 64

Idiopathic Pulmonary Fibrosis-Pipeline by Promedior, Inc., H1 2015 65

Idiopathic Pulmonary Fibrosis-Pipeline by ProMetic Life Sciences Inc., H1 2015 66

Idiopathic Pulmonary Fibrosis-Pipeline by Pulmatrix, Inc., H1 2015 67

Idiopathic Pulmonary Fibrosis-Pipeline by Sanofi, H1 2015 68

Idiopathic Pulmonary Fibrosis-Pipeline by Therametrics holding AG, H1 2015 69

Assessment by Monotherapy Products, H1 2015 70

Assessment by Combination Products, H1 2015 71

Number of Products by Stage and Target, H1 2015 73

Number of Products by Stage and Mechanism of Action, H1 2015 76

Number of Products by Stage and Route of Administration, H1 2015 78

Number of Products by Stage and Molecule Type, H1 2015 80

Idiopathic Pulmonary Fibrosis Therapeutics-Recent Pipeline Updates, H1 2015 158

Idiopathic Pulmonary Fibrosis-Dormant Projects, H1 2015 197

Idiopathic Pulmonary Fibrosis-Discontinued Products, H1 2015 198

List of Figures

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2015 14

Number of Products under Development for Idiopathic Pulmonary Fibrosis-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 16

Number of Products under Investigation by Universities/Institutes, H1 2015 21

Comparative Analysis by Clinical Stage Development, H1 2015 23

Comparative Analysis by Early Stage Products, H1 2015 24

Assessment by Monotherapy Products, H1 2015 70

Number of Products by Top 10 Targets, H1 2015 72

Number of Products by Stage and Top 10 Targets, H1 2015 72

Number of Products by Top 10 Mechanism of Actions, H1 2015 75

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 75

Number of Products by Top 10 Routes of Administration, H1 2015 77

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 78

Number of Products by Top 10 Molecule Types, H1 2015 79

Number of Products by Stage and Top 10 Molecule Types, H1 2015 80

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AdAlta Pty Ltd.

Aeolus Pharmaceuticals, Inc.

AnaptysBio, Inc.

Auspex Pharmaceuticals, Inc.

Biogen Idec Inc.

Bioneer Corporation

BiOrion Technologies B.V.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Carolus Therapeutics, Inc.

Celgene Corporation

Chong Kun Dang Pharmaceutical Corp.

Compugen Ltd.

F. Hoffmann-La Roche Ltd.

FibroGen, Inc.

Five Prime Therapeutics, Inc.

GenKyoTex S.A.

Gilead Sciences, Inc.

GlaxoSmithKline plc

HanAll Biopharma Co., Ltd.

Histocell S.L.

iBio, Inc.

ImmuneWorks, LLC

Inventiva SAS

Kadmon Corporation, LLC

Kasiak Research Pvt. Ltd.

Kyorin Pharmaceutical Co., Ltd.

Lanthio Pharma B.V.

LTT Bio-Pharma Co., Ltd.

MedImmune, LLC

Moerae Matrix, Inc.

MSM Protein Technologies, Inc.

Pacific Therapeutics Ltd.

Pharmaxis Limited

Progenra, Inc.

Promedior, Inc.

ProMetic Life Sciences Inc.

Pulmatrix, Inc.

Sanofi

Therametrics holding AG

Idiopathic Pulmonary Fibrosis Therapeutic Products under Development, Key Players in Idiopathic Pulmonary Fibrosis Therapeutics, Idiopathic Pulmonary Fibrosis Pipeline Overview, Idiopathic Pulmonary Fibrosis Pipeline, Idiopathic Pulmonary Fibrosis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com